In this issue:
Cilta-cel effective and safe in real-world RRMM
Deciphering the mechanisms driving CAR T-related cytopenia
MajesTEC-1: teclistamab safe and efficacious after BCMA-directed therapy
Should bispecifics be the standard of care for post CAR T-cell therapy relapse?
CAR T safe and effective in patients with concurrent AL amyloidosis
Preclinical evaluation of a CD38/CD3xCD28 trispecific T-cell engager
Quadruplet regimens improve outcomes vs triplets in newly diagnosed disease
Does frailty portend inferior outcomes after ASCT?
MYC translocation could be a marker of extramedullary disease
Subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma
Please login below to download this issue (PDF)